Cargando…
Treatment Courses of Patients Newly Diagnosed with Multiple Sclerosis in 2012–2018
Treatment options for multiple sclerosis (MS) are now numerous, but it is unclear which Disease-Modifying Treatment (DMT) is the optimal choice for a given patient. Treatment switches are common, both because of side effects and because of lack of efficacy. There are few data available on the treatm...
Autor principal: | Sipilä, Jussi O. T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866399/ https://www.ncbi.nlm.nih.gov/pubmed/36675522 http://dx.doi.org/10.3390/jcm12020595 |
Ejemplares similares
-
Vaccination frequency in people newly diagnosed with multiple sclerosis
por: Darvishi, Sonia, et al.
Publicado: (2023) -
Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States
por: Kern, David M., et al.
Publicado: (2020) -
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013) -
Activated monocytes and markers of inflammation in newly diagnosed multiple sclerosis
por: Carstensen, Mikkel, et al.
Publicado: (2020) -
Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
por: Rauma, Ilkka, et al.
Publicado: (2021)